What is it about?
This comprehensive review synthesizes literature from 2004 to 2020 on the phytochemistry and pharmacological potential of volatile and non-volatile constituents—including terpenes, flavonoids, alkaloids, phenolics, tannins, and essential oils—derived from the genus Melaleuca (Myrtaceae), commonly known as tea tree. Historically valued in Australian traditional medicine for its broad-spectrum antimicrobial activity, the genus exhibits diverse biological properties, including potential inhibitory effects against COVID-19. By consolidating these research findings, the article serves as a strategic resource for pharmacologists and medicinal chemists seeking to isolate bioactive compounds, optimize clinical applications, and advance the development of novel plant-derived therapeutic agents.
Featured Image
Photo by Sinah Niepel on Unsplash
Why is it important?
This review is important because it bridges traditional medicine and modern drug discovery by offering a systematic overview of sixteen years (2004–2020) of research on the phytochemistry and biological activities of both volatile and non-volatile compounds from the Melaleuca genus. By demonstrating how key secondary metabolites—such as terpenes, flavonoids, and essential oils—contribute to broad antimicrobial and therapeutic properties (including potential inhibitory effects against COVID-19), the study provides researchers and pharmaceutical developers with a clear roadmap for isolating active compounds and translating traditional Australian herbal remedies into standardized, novel clinical drugs.
Perspectives
The perspectives of this study lie in translating sixteen years of phytochemical and pharmacological data on the genus Melaleuca into actionable strategies for drug discovery, clinical formulation, and antiviral research. By mapping out both volatile (essential oils) and non-volatile (phenolics, flavonoids, tannins) bioactive components, the review establishes a foundation for researchers to isolate single molecular compounds (such as 1,8-cineole or terpinen-4-ol) and evaluate their synergistic mechanism against emerging pathogens, including SARS-CoV-2. Furthermore, it highlights the transition from traditional, crude botanical preparations to standardized pharmaceutical products, encouraging future preclinical in vitro/in vivo assays, molecular docking studies, and structured clinical trials aimed at expanding Melaleuca-derived compounds into therapeutic candidates for broad-spectrum antimicrobial and respiratory antiviral therapies
Dr Mayssaloune Ali Kanso
Beirut Arab University
Read the Original
This page is a summary of: GENUS MELALEUCA: PHYTOCHEMISTRY, PHARMACOLOGY AND EFFECT AGAINST COVID-19, BAU Journal - Health and Wellbeing, April 2022, Beirut Arab University,
DOI: 10.54729/kmci3389.
You can read the full text:
Contributors
The following have contributed to this page
